Stocks waver as confidence falls in Europe
Stocks closed down modestly after opening low and recovering in the afternoon. Stocks had risen strongly in recent weeks as traders anticipated, then received, help from the Federal Reserve.
U.S. stocks meandered sideways Monday as fears about Europe overshadowed recent excitement about central banks' efforts to boost the market.Skip to next paragraph
Subscribe Today to the Monitor
Stocks opened lower, recovered by mid-afternoon to nearly flat and closed down modestly.
An index of business confidence in Germany, the biggest economy in Europe, fell for a fifth straight month. Many economists had expected it to at least remain flat. Some think Germany is headed for a recession.
The threat of the years-old European debt crisis has seemed less immediate in recent weeks as central banks unveiled measures aimed at encouraging investment and boosting the global economy. The German report reignited those fears.
Stocks had risen strongly in recent weeks as traders anticipated, then received, help from the Federal Reserve in the form of an open-ended bond-buying program. The Fed will buy $40 billion of mortgage bonds per month until the economy has improved.
"It's not unusual after big moves for the market to, in essence, go quiet and wait for the next catalyst," said Quincy Krosby, market strategist with Prudential Financial. The next catalyst, Krosby said, is third-quarter earnings, which companies will begin to announce next month.
The Dow Jones industrial average closed down 20.55 points, or 0.2 percent, at 13,558.92. The Standard & Poor's 500 index declined 3.26, or 0.2 percent, to 1,459.89. Its two strongest groups were utilities and telecommunications, safer stocks that tend to do well in a weaker economy.
As in the U.S., the concern in Germany is that an economy on the rebound will be weighed down by the rest of the European countries, half of which are already in recession.
Germany's economy grew 0.3 percent in the second quarter from the previous quarter, but a number of economists now believe the country will fall into a recession in the second half of the year.
In the U.S., stocks have gone from underpriced to fairly priced, said Doug Cote, chief market strategist at ING Investment Management. If recent weakness in U.S. manufacturing is any guide, he said, traders will be disappointed next month by companies' quarterly results.
"It will be a sea change — the first time in three years that we've had negative earnings growth," Cote said. He said China's abrupt economic slowdown is adding to corporate America's woes.
If that happens, Krosby said, it could drive the market lower. Without enough positive surprises from companies this quarter, the Fed program probably won't be enough to extend the rally, she said.
"There's an uneasy feeling surrounding the market," she said.
In the U.S., traders are looking for more good news from the housing market, which appears to be bouncing back after being a stuck in a rut for years. The latest data on new and pending home sales will be released later in the week.
Lennar on Monday became the latest builder to post surprisingly strong earnings. A rise in orders and the number of homes delivered, adding to a big tax benefit, had the Miami homebuilder quadrupling profits. KB Home on Friday did almost as well, and housing shares jumped on optimistic comments from its CEO, Stuart Miller.
On Monday, Lennar closed down 55 cents, or 1.5 percent, at $36.96. KB Home fell 63 cents, or 4.1 percent, to $14.63.
Apple fell after sales of the new iPhone 5 missed analysts' targets. The company sold 5 million units in three days. Its stock fell $9.31, or 1.3 percent, to $690.79.
UnitedHealth Group was down slightly on its first day in the Dow, which shuffled its lineup of stocks to reflect health care's growing importance in the economy. UnitedHealth, the nation's largest health insurer, replaces Kraft Foods in the Dow. Its stock fell 20 cents, or 0.4 percent, to $55.98.
Peregrine Pharmaceuticals Inc. stock collapsed after the cancer drug developer told analysts they should not rely on recently disclosed data about its lead product, a proposed lung cancer treatment. The stock fell $4.23, or 78.5 percent, to $1.16.
The price of oil fell to around $92 a barrel, dragged down by concerns about weakening global growth and demand for crude. Benchmark crude fell 96 cents, or 1 percent, to settle at $91.93 per barrel on the New York Mercantile Exchange.
Stronger demand for safe investments pushed the yield on the 10-year Treasury note down to 1.72 percent from 1.75 percent late Friday.